Clinical Talks is back!

Published 30 August, 2021Events, Seminar

We have the great pleasure to announce that Clinical Talks” has been renewed for yet another exciting, innovative, and enlightening season. This season will focus on sustainable innovations within Life Sciences, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations.

Season 5, will start September 3 with Dr. Karim Cassimjee, World Economic Forum delegate, and inventor and co-founder behind EnginZyme AB. The season will and go on until December 2021 with a minimum of seven scheduled Talks, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community, both Clinical, Scientific, educational, as well as industry professionals.

Below follows a short description of each talk.

To signup, please use the website link below.

Registration

First out on September 3. Dr. Karim Cassimjee, World Economic Forum delegate, and inventor and co-founder behind EnginZyme AB, whose technology can radically change the way the chemical industry functions today, resulting in significantly lower climate footprints.

On September 9, we will host a dual presentation held by Olink co-founder Dr. Simon Fredriksson and Dr. Andrea Ballagi, Olink Proteomics VP Sales and Marketing. The talk will feature a dual presentation, showcasing the visionary development of the power a technological platform can have, and how it became a market leading diagnostic tool that today shows the promise to highly effectivize the way medical diagnostics and treatment options are done in a more sustainable way.

On September 30, Dr. Hyunsung John Kim, will talk about the amazing potential RNA liquid biopsies can offer modern healthcare, by detecting cancer early, while it still can be cured. Resulting in a total transformation of cancer care, ultimately allowing for a more efficient, cost-effective, and sustainable healthcare. While working as a senior Bioinformatician at Illumina, John was part of the founding team who branched out GRAIL, with its very promising Galleri multi-cancer early detection test soon to hit our Clinical reality.

On October 15, it’s our great pleasure to host Professor Emma Lundberg once again. This time she will focus her Talk on her innovative company Mindforce GameLab. With the Fig platform, patients can via gamification transform into “playtients”, people with medical conditions who enjoy playing games with a purpose to establish healthy habits. Fig guides you on the journey to better health, including improved behavioral administration of medicals for intended and sustainable use.

On October 21, Dr. Emily Leproust will talk about her mission with co-founding Twist Bioscience, and how their revolutionary oligosynthesis plattform is writing the future with DNA. With previously unprecedented lengths, costs, and industrial scalability it’s a real game changer in the Life Science industry. DNA tools can now be used in fields as medicine (diagnostics, vaccines, and therapeutics), agriculture, industrial chemicals, and data storage. Twist Bioscience enables the users to develop ways to better lives and improve the sustainability of the planet.

On October 29, we will host a dual presentation with Dr. Ina Stelzer and Associate Professor Brice Gaudilliere. In the Stanford School of Medicine Clinical Gaudilliere lab, Ina and Brice have developed an groundbreaking multi-omics diagnostic tool in order to track the maternal metabolome, proteome and immunome to predict exact labor onset. Estimating the time of delivery is of high clinical importance to minimize pre- and post-term deviations causing complications and suffering with ultimately more streamlined use of medical resources for a sustainable future.

On November 26, we will host Karolinska Institute (KI) Professor Richard Rosenquist Brandell. In addition to his academic research and clinical work, he also co-founded the Genomic Medicine Sweden (GMS) initiative and serves as the Director of GMS. Richard will share his insights on Sweden’s national strategy to implement Precision medicine into our healthcare environment and pave the road for all the amazing the potential the approach has to offer. To benefit from the sustainable advantages of tailored and efficient use of diagnostics and treatment options, Sweden needs to prepare our society for the legal challenges and infrastructures needed to support and enable this transformation.

On December 3, Uppsala University Associate Professor Sara Mangsbo will end the season with her Talk about how the future of cancer therapy is becoming personal. Sara co-founded Strike Pharma to further develop the Uppsala University and SciLifeLab Drug Discovery platform co-developed ADAC technology (Adaptable Drug Affinity Conjugates). With patient specific multi-omics profiles, the delivery platform enables patient tailored neoantigen cocktails ensuring that the body becomes a factory producing billions of T Cells that can find and destroy tumor cells regardless of the location in the body. With a “True Precision Medicine” approach, therapeutics will be more efficient and ultimately lowering the healthcare burden for a sustainable future.